Radiation Oncology Department, Centre de Lutte Contre le Cancer Léon Bérard, Lyon, France.
Department of Radiation Oncology, Hôtel-Dieu de France University Hospital, Saint Joseph University, Beirut, Lebanon.
Curr Opin Otolaryngol Head Neck Surg. 2022 Apr 1;30(2):137-144. doi: 10.1097/MOO.0000000000000795.
The use of external beam radiation therapy (EBRT) for the treatment of the different histologic subtypes of thyroid cancer is a matter of debate. This article provides an up-to-date review on the current evidence concerning the benefits of EBRT in thyroid cancer in specific indications.
Based on retrospective studies, adjuvant EBRT lessens the risk of locoregional recurrence in locally advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) with high-risk features. The effect of EBRT on overall survival remains uncertain. EBRT should also be part of the multimodality treatment in anaplastic thyroid cancer (ATC), as it improves survival rates in incompletely resected ATC.
The role of EBRT in thyroid cancer remains unclear. To date, no randomized control studies are available. Retrospective data showed improved outcomes in patients with high-risk features for locoregional recurrence.
对于不同组织学类型的甲状腺癌，使用外部束放射治疗（EBRT）的治疗方法存在争议。本文提供了有关 EBRT 在特定适应证中治疗甲状腺癌的最新证据的综述。
基于回顾性研究，辅助 EBRT 可降低局部晚期分化型甲状腺癌（DTC）和具有高危特征的髓样甲状腺癌（MTC）的局部区域复发风险。EBRT 对总生存率的影响仍不确定。EBRT 也应作为间变性甲状腺癌（ATC）的多模态治疗的一部分，因为它可提高不完全切除的 ATC 的生存率。
EBRT 在甲状腺癌中的作用仍不清楚。迄今为止，尚无随机对照研究。回顾性数据显示，对于有局部区域复发高危特征的患者，EBRT 可改善结局。
